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Abstract 
Safety control tests for vaccines need to be capable of quantifying in vivo toxicity of vaccines. Endotoxin contamination is a 
threat for vaccine safety and has traditionally been controlled using either an in vivo rabbit pyrogen test or the in vitro Limulus 
amebocyte lysate (LAL) assay. An in vitro pyrogen test was developed using prostaglandin E2 induction in rabbit peripheral 
blood. Responsiveness of LAL and rabbits to various endotoxins, however, differ from that of humans. A monocyte activation 
test was developed using human monocytes but is not applicable where the use of donated blood is limited to therapeutic 
purposes. Therefore, a clinically relevant in vitro pyrogen test was developed using a human monocytic cell line responsive to 
various pyrogens in a manner consistent with that of human peripheral blood. Residual pertussis toxin (PT) activity of acellular 
pertussis vaccines (aPs) is quantified by the mouse histamine sensitization (HS) test. The Chinese Hamster Ovary Cell clustering 
test can sensitively detect PT activity but is not adequate for testing aPs due to hampered interaction of aggregated PT molecules 
with cell surface receptors. An in vitro test system has been developed to estimate HS activity using the combined assay results 
of carbohydrate binding ELISA (B-subunit) and enzymatic-HPLC (A-subunit). Potency tests need to evaluate protective 
immunogenicity of vaccines. Protective potency of whole cell pertussis vaccine can be measured by the method whose results 
were shown to correlate with clinical protection. Identifying and quantifying the structures of antigen molecules relevant to the 
induction of protective immunity may be the ultimate goal. 
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1. Introduction 
Vaccines typically are composed of complicated macromolecular antigens of biological origin manufactured in a 
batch-wise procedure. As such, the possibility of inherent batch-to-batch quality variation exists which could impact 
final lot consistency. This variation may not always be reflected in the variation of a limited number of pilot lots 
and, therefore, quality control tests and post marketing surveillance are of critical importance.  
Vaccines may have various undesirable biological activities other than protective immunogenicity. Those 
activities may include residual activity of detoxified or attenuated vaccine antigens, unspecified components from 
the culture of vaccine production strains or ubiquitous toxic substances such as endotoxin. Any activities not 
relevant to protective immunogenicity need to be controlled or, if feasible, eliminated. Although the link between 
any such biological activities with adverse reactogenicity may not be readily identifiable, a vaccine is unlikely to 
cause adverse reactions without such associated biological activities. Some of these activities may involve cytokine 
induction or modification of immune responses in their mechanism of action. Such immunomodulating activity may 
lead to excess inflammation of injection sites or sensitization to extensive reactions including local reactions to 
successive doses [1, 2]. In general, clinical tolerability of local reaction is evaluated based only on the surface 
observation of injection sites while possible tissue damage is not evaluated. Preclinical evaluation is carried out by 
using a similar procedure for chemicals and is not always adequate for evaluating immune response-related local 
reactivity of vaccines [3]. Local reactivity in terms of the tissue damaging effect of vaccines needs to be evaluated in 
comparison with a vaccine with sufficient history of clinical tolerability in appropriate animal models [1, 4]. It is 
important to analyze the mechanism of local reactivity of a vaccine when searching for replacement test methods.  
Vaccine quality control based on production consistency, if feasible, can effectively reduce the number of 
necessary control tests and, accordingly, of animal use. Lot-to-lot consistency of chemical drugs can be assured 
based on structural analysis. However, due to the structural complexity of antigen molecules, assuring lot 
consistency of vaccines is usually based on ensuring that a set of parameters is within specified ranges. The 
parameters and ranges are selected so as to reflect those of clinical trial lots that were extensively evaluated for 
safety in humans. Therefore the value of vaccine control tests is in ensuring consistency with clinical trial lots whose 
safety and effectiveness has been previously shown in clinical studies [5,6]. However, actual clinical relevance of 
the parameters might not have always been elucidated. Even adequate procedures for detecting or evaluating some 
important parameters may not yet be available. Therefore, some selected parameters may not be relevant and other 
relevant parameters may not be included. Furthermore, such parameter monitoring requires a reference material that 
represents, as exactly as possible, characteristics of clinical trial lots. As even freeze-thawing for lyophilizing may 
affect the characteristics, it may not be feasible to establish a stabilized reference material reliably representing the 
characteristics of the original clinical trial lot. Some drift in quality of successive lots of the reference material and, 
correspondingly, product lots would be inevitable if successive lots of reference material were used without the 
assurance of stability. Cumulative drift in quality of such successive lots of reference material may even lead to the 
loss of traceability to the clinical trial lots. The approach based on successive lots of product-specific reference 
materials would be reliable for ensuring product consistency only when the selected properties for parameter 
monitoring are very stable and include all detectable biological activities. Therefore, it seems of critical importance 
to have reliable control tests standardized using stabilized and reliably calibrated standard preparations and to 
encourage the development of well-standardized test methods based on stabilized standard preparations.  
Even similar vaccines from different manufacturers may have been produced using different production strains 
under different culture conditions and may have employed different procedures of purification and detoxification. 
Therefore, each of these products is regarded as unique and may not be comparable with others using universally 
applicable control tests [5,6]. If this were really the situation, all alternative tests would also be product-specific to 
compare only with product-specific reference materials. However, all such vaccine products, if efficacious, should 
have the common structures of antigen molecules necessary for inducing protective immunity against the same 
disease or common virulence factors of the same pathogen. Accordingly, a reliable potency test for such a vaccine 
should be applicable to all the similar vaccine products as they share common essential structures of antigen 
molecules for the induction of protective immunity. Therefore, all such similar vaccine products should be cross-
reactive and may even boost the immune response to a primary dose with a similar product from a different 
manufacturer. Therefore, universal control tests reliably standardized against stabilized reference preparations may 
be feasible. Accordingly, it is possible to develop an alternative in vitro potency test once the antigens and their 
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structures necessary for the protective immune response have been identified. Effective development of alternative 
test methods need, therefore, to focus on such reliably standardized test methods. 
2. Safety testing - alternative in vitro tests for the detection of endotoxin 
Endotoxin is the most potent pyrogen and is controlled using either the rabbit pyrogen test or, more recently, the 
limulus amoebocyte lysate (LAL) endotoxin test. The rabbit pyrogen test measures the fever response in rabbits post 
injection of the test compound (e.g. vaccine). The LAL method reacts hemolymph (blood) from a horseshoe crab 
(Limulus polyphemus) with an endotoxin-containing product to form a gel; quantitation of the endotoxin level is 
determined by comparing the dilution of gel formation of a test sample to that of a reference pyrogen. The pyrogen 
test in rabbits has a long history of controlling pyrogenicity of pharmaceuticals for injection but owing to its use of 
animals and associated variability and the development of potential in vitro alternatives, it is currently a primary 
target for replacement. The LAL test is considered to be specific for the presence of endotoxins and is at least a 
hundred times more sensitive than the rabbit test. In the mid 1980s, the LAL endotoxin test in Japan was used only 
to assess endotoxin levels in distilled water for injection. Its application to biologics including blood products and 
interferon injections became possible with the improvement of specificity of the reagents to allow reliable validation 
based on the correlation with the rabbit pyrogen test.  
Implementation of the LAL endotoxin test in Japan was expanded to most antibiotics, blood products and also to 
some vaccines [7, 8, 9]. In the course of expanding the application, augmenting effects of interferon (IFN) alpha, 
human serum albumin and purified protein fraction injections on in vivo pyrogenicity of endotoxin were identified in 
rabbits. According to the finding, Japanese endotoxin limits for biologics were defined by taking such in vivo 
augmenting effect into account instead of a uniform limit value for various products. Although the pyrogen test is 
the primary target for replacement, the LAL endotoxin test is not itself appropriate for evaluating in vivo toxicity of 
endotoxin contamination in augmenting biologics. Therefore, we (NIID) have developed an in vitro pyrogen test 
using prostaglandin E2 (PGE2) induction in rabbit peripheral blood (10). The new in vitro pyrogen test is highly 
sensitive and accurate and is comparable to the in vivo pyrogen test. When test samples were compared to standard 
endotoxin, the results were extremely reproducible even in blood from different rabbits [10]. 
We compared responsiveness of LAL, rabbits, rabbit peripheral blood, and human peripheral blood to endotoxins 
from various bacterial sources. We used commercially available endotoxins to allow comparison of results with 
other laboratories. As shown in Table 1, different endotoxins showed different amounts of LAL activating activity 
when assessed at the same concentration in terms of weight per milliliter. Additionally, rabbits and rabbit peripheral 
blood showed highly consistent responsiveness to various endotoxins but their responsiveness completely differed 
from that of human peripheral blood [11]. In spite of the difference in responsiveness from human blood, the in vitro 
pyrogen test using rabbit blood can be a useful alternative for the pharmaceuticals that still require the rabbit 
pyrogen test. 
The monocyte activation test (MAT) using human peripheral blood is a clinically relevant in vitro pyrogen test 
and was approved in Europe but is not applicable in some countries including Japan due to the prohibition on the use 
of donated blood for other than therapeutic purposes. Therefore, we developed a clinically relevant in vitro pyrogen 
test using a human monocytic cell line of embryonic origin, 28 SC cells [11]. The cells needed at least 40 sub-
cultures in endotoxin-free medium to improve the sensitivity. The cell line was found to have highly consistent 
responsiveness to various endotoxins compared with that of human peripheral blood (Figure 1). However, the cells 
are very fragile for use in routine tests in laboratories. We would propose the use of the in vitro pyrogen test in 28 
SC cells to define the clinically relevant endotoxin limits for LAL test. Although control of pyrogenicity is crucial 
for vaccines, currently the pyrogen test or endotoxin test has been implemented for only limited types of vaccines. 
As cytokines such as IFN augment in vivo action of endotoxin [11] and some vaccines, particularly viral vaccines, 
may induce cytokines, endotoxin limits for vaccines may need to be defined by using the clinically relevant cell line 
test. Therefore, the in vitro pyrogen test using the human monocytic cell line may be a useful supplement and/or 
alternative to the current pyrogen test for pharmaceuticals for which the LAL endotoxin test is not applicable and 
also for those that augment the in vivo action of endotoxin. 
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Table 1. Relative activities of endotoxins 
Endotoxin 
EU equivalent/weight EU/weight 
Rabbita PGE2b hPBCc LAL 
E. coli UKT B 1.000 1.000 1.000 1.000 
E. coli O113 0.688 0.154 0.025 0.313 
E. coli O111 5.078 1.527 0.813 1.563 
E. coli O55 3.203 1.154 0.593 1.063 
E. coli O127 3.072 1.331 0.015 1.563 
S. typhosa 0.902 0.373 0.001 0.188 
S. abortus equi 3.523 1.388 1.364 0.781 
P. aeruginosa 0.156 0.173 0.457 0.625 
K. pneumoniae 3.385 1.853 0.368 1.250 
V. cholerae Inaba 
569B 
0.058 0.022 0.001 0.880 
aPyrogenicity in rabbits measured quantitatively.  
bPGE2 induction in rabbit peripheral blood.  
cIL6 induction in human peripheral blood.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3. Safety testing – alternative in vitro tests for the detection of residual pertussis toxin activity in acellular 
pertussis vaccines 
Vaccine evaluation for initial licensure has critical value. However, it is not always feasible to fully characterize a 
vaccine at its initial development and critical scientific issues relating to safety may be identified afterwards. Once a 
vaccine is licensed based on a certain extent of clinical tolerability, it is usually not possible to clinically re-evaluate 
or revise the licensure of the vaccine according to such findings. Such novel findings may be critical for vaccine 
Figure 1. Clinically relevant in vitro pyrogen test in 28SC cells. 
A monocytic cell line of human embryonic origin, 28SC, showed responsiveness to various endotoxins in IL-6 production quite consistent 
with that of human peripheral blood.  
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improvement but such improvements are not regarded as essential. Therefore, novel laboratory research on possible 
reactogenicity of vaccines may not attract attention. The original Japanese acellular pertussis vaccine (aP vaccine) 
was found to revert to pertussis toxin (PT) toxicity several years after its implementation [12]. Although the possible 
clinical impact of the reversion to toxicity was not fully ascertained, Japanese Minimum Requirements were revised 
to intensify the detoxification in production process based on the theoretical safety concern. This revision was later 
shown to have been effective at least in reducing the possibility of severe local reactions [1, 4].  
Vaccines may also have various biological activities other than protective immunogenicity. With regard to safety, 
any activities not relevant to protective immunogenicity need to be controlled or, if feasible, eliminated. In general, 
vaccines are composed of detoxified virulence factors or attenuated pathogens. It is therefore crucial to demonstrate 
the detoxification or attenuation of vaccines to ensure their safety. All aP vaccines contain detoxified PT and 
therefore control of residual PT activity is an important component of safety control. The mouse histamine 
sensitization (HS) test, based on increased sensitivity of mice treated with PT to histamine challenge, is used for 
measuring residual activity of PT in aP-containing vaccines. The traditional HS test is based on fatal sensitization of 
mice to histamine [13] and has been used in Europe and the United Sates. An in vitro CHO cell clustering test was 
developed and found to be highly sensitive with the ability to detect approximately ten pg/mL of PT. However, due 
to the aggregation of the PT molecules created during detoxification, the test was found not suitable as the aggregate 
hampered direct interaction of PT molecules with cell surface receptors [16].  
An alternative test method developed in Japan and used in Asian countries, is based on body temperature 
reduction after histamine challenge depending on the extent of sensitization with PT [14]. This method does not 
always require fatal sensitization of mice and, therefore, can detect lower levels of PT activity that does not fatally 
sensitize mice. Furthermore, the temperature method uses a continuous variable (temperature) instead of quantal 
response value (mortality rates) and, therefore, has better precision compared to the traditional fatal sensitization 
method. The assay can be simplified to use only one appropriate dose of a test sample instead of multiple doses after 
validating the parallelism of dose response of test samples with that of the standard or reference preparation [15]. 
The simplified temperature method requires three or four groups of mice for the standard preparation and one group 
for a test sample and can effectively reduce the number of mice by testing multiple samples simultaneously.  
Further development of a potential alternative to the in vivo HS test was made by estimating HS activity by an 
equation using results of a fetuin-binding ELISA (B-subunit) and enzyme-coupled HPLC (A-subunit) [17]. The 
equation needed to be estimated for each product separately because different aP products employ different 
detoxifying conditions that may differently impact residual activities of subunits, although they all may be retaining 
the common protective immunogenicity. As shown in Figure 2, estimated HS activity was shown to be highly 
consistent with that of in vivo HS activity. In the course of estimating the equation for an aP product, marked batch-
to-batch variation of residual B-subunit activity was noted. This was common to most of the aP products tested and 
suggested the limitation of the approach of controlling vaccine quality based only on production consistency and 
justified also the importance of control tests. The finding also suggests a possible advantage of in vitro tests for 
assessing activities of subunits separately over an in vivo test for holotoxin (a protein toxin comprised of several 
subunits) activity. B-subunit activity of PT was reported to be relevant to adjuvant effect on co-administered 
antigens and, according to an investigation in a mouse model, may cause extensive sensitization of vaccinees due to 
residual activities of S2/3 to local swelling responses to booster doses through receptor-binding and 
immunopotentiation (Preparing for publication) [18,19,20]. The fetuin-binding ELISA may assess this residual B-
subunit activity. Further investigation is necessary on the possible relevance of holotoxin activity of PT to any 
adverse reactogenicity of aP. 
4. Potency testing – alternative serological potency assay for pertussis vaccine 
Potency tests are used for determining the protective immunogenicity of vaccines. Furthermore, clinically 
relevant potency tests may have a critical value in addressing the difficulty of monitoring clinical efficacy after 
eliminating disease prevalence. The test results need to clearly correlate with clinical protection but such a 
protection model does not need to completely mimic the clinical infection and protection. Figure 3-A represents the 
correlation between probit-transformed household attack rate and potency test results of whole cell pertussis 
vaccines measured by the mouse intracerebral challenge test [21]. The correlation was much clearer when potency 
test results from a single laboratory were used [22] (Figure 3-B). Even if the mechanism and relevant antigens were  
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not completely consistent with those involved in clinical protection, the test has significant value as the results show 
a clear correlation with clinical protection. If fewer antigens are involved in an animal protection model compared to 
those in clinically protective vaccine products, then a vaccine that contains these antigens, plus additional protective 
antigens not evaluated in the model, may also be regarded as clinically protective. All currently available aPs 
contain detoxified PT and aPs composed of detoxified PT alone were shown to be protective both clinically and also 
in animal models [23, 24,25], although some intensified protection is reported for additional antigens such as FHA, 
pertactin or fimbriae [23]. The original co-purified aPs comprised mainly PT and FHA but included all relevant 
antigens produced by the bacteria [26] and, therefore, potency basically could be assessed by the same assay method 
as wP. As all similar vaccine products from different manufacturers should be able to induce a protective immune 
response against the same disease, they should be cross reactive and be capable of boosting the immunity to the 
similar products from different manufacturers even without consistency in production process between the priming 
and boosting products. Although the mechanisms of protection in the model and clinical protection need to be 
elucidated further, development of an alternative method for evaluating structures or functions of vaccine antigens 
that induce protective immunity may be feasible and need to be encouraged. 
Serological assays using ELISAs have been proposed as alternatives to in vivo potency tests [27, 28]. However, 
without assessing serological correlates of protection, the results of ELISAs alone may not assure protective 
immunity. Such a serological assay needs to be validated against an assay for the protective function. Furthermore, 
where immunity to a toxin is likely to be relevant, it is possible to measure the neutralizing function of antibodies 
against the toxin if a method for assessing toxin activity is available. However, such functional assays should not be 
regarded as automatically relevant to protection because protection could be dependent on the mechanisms of action 
of toxin in the toxicity assay system and also on the roles of toxin in the infection and of immunity against the toxin 
in protection. It is claimed that the primary purpose of such serological assays is to ensure product consistency 
rather than for predicting protective efficacy. However, consistency monitoring is meaningful only when ensuring 
consistency of parameters that are actually relevant to protection. Furthermore, such a serological consistency 
approach cannot address the difficulty of evaluating clinical efficacy once the disease is no longer prevalent. In such 
a situation reduction in the protective activity of the vaccine will only be indicated by resurgence of disease. 
Therefore, new vaccine developments and also modifications of the production process, which may impact 
protective function, may lead to serious difficulties without a clinically relevant protection model.  
 
Figure 2. In vitro histamine sensitization test for acellular pertussis vaccines (aP) 
There was excellent correlation between in vivo HS activity and that calculated by equations estimated separately for each product using Fetuin-
binding (B-subunit) and HPLC-coupled enzymatic (A-subunit) assay results. 
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